Sugi Predict

Sugi Predict / Compounds / SCHEMBL255099

SCHEMBL255099

SCHEMBL255099

c1ccc(CN2CCCNCC2)cc1

nearest known ligand 0.85

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 3/20 0.85
▸ CXCR4 P61073 13/20 0.77
▸ MEN1 O00255 2/20 0.77
▸ KMT2A Q03164 2/20 0.77
▸ CHRM2 P08172 1/20 0.77
▸ CHRM1 P11229 1/20 0.77
▸ ADRA2C P18825 1/20 0.77
▸ CCR2 P41597 1/20 0.77
▸ CXCL12 P48061 1/20 0.77
▸ BLM P54132 1/20 0.77
▸ TDP1 Q9NUW8 1/20 0.77
▸ HRH3 Q9Y5N1 1/20 0.77
▸ ALDH1A1 P00352 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ HIF1A Q16665 1/20 0.60
▸ CYP2D6 P10635 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10316935 1.00 SIGMAR1 (0.85) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL31616422 0.98 SIGMAR1 (0.82) SIGMAR1CXCR4MEN1KMT2ACHRM2
Hydrochloric Acid SCHEMBL7422770 0.98 SIGMAR1 (0.82) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL3994310 0.96 CXCR4 (0.83) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL3779720 0.96 CXCR4 (0.78) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL30641657 0.95 CXCR4 (0.81) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL6632216 0.95 SIGMAR1 (0.82) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL15046526 0.94 CXCR4 (0.75) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL3999326 0.93 CXCR4 (0.79) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL15043649 0.93 SIGMAR1 (0.85) SIGMAR1CXCR4MEN1KMT2ACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118406439-B Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-10-18 — — CN claimed
CN-118406439-A Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-07-30 — — CN claimed
CN-114957163-B Preparation method of N-methyl homopiperazine 合肥亿帆生物制药有限公司 2024-05-10 — — CN claimed
CN-115093794-B Polysilicon polishing composition and application thereof 万华化学集团电子材料有限公司 2023-10-13 — — CN claimed
CN-115093794-A Polysilicon polishing composition and application thereof 万华化学集团电子材料有限公司 2022-09-23 — — CN claimed
CN-114957163-A Preparation method of N-methyl homopiperazine 合肥亿帆生物制药有限公司 2022-08-30 — — CN claimed
CN-214991239-U Ice-water cooling device for preparing benzyl homopiperazine 南京超逸生物科技有限公司 2021-12-03 — — CN claimed
CN-211487697-U Benzyl homopiperazine preparation raw materials reaction unit 武汉利昌医药科技有限公司 2020-09-15 — — CN claimed
CN-211383856-U Rectification and purification device for preparing benzyl homopiperazine 武汉利昌医药科技有限公司 2020-09-01 — — CN claimed
CN-210815161-U 1-benzyl homopiperazine synthesis reactor 四川久凌制药科技有限公司 2020-06-23 — — CN claimed
CN-110343077-A A kind of 1- benzyl homopiperazine alkane separation method 四川久凌制药科技有限公司 2019-10-18 — — CN claimed
CN-102797043-B Medicinal molecular fragment library and construction process thereof Tianli (Tianjin) Technology Co., Ltd. (CN) 2015-11-25 — — CN claimed
CN-104876893-A Substituted-homopiperzine dithiocarbamic acid bismuth complexes, and medicinal salts, preparation methods and antitumor application thereof UNIV NANYANG NORMAL 2015-09-02 — — CN claimed
US-20100075966-A1 Substituted Dihydroimidazoles and their Use in the Treatment of Tumors NOVARTIS AG 2010-03-25 — — US claimed
EP-2097386-A2 SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS Novartis AG (CH) 2009-09-09 — — EP claimed
WO-2008065068-A2 SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR USE IN THE TREATMENT OF TUMORS NOVARTIS AG (CH) 2008-06-05 — — WO claimed
EP-1406900-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2004-04-14 — — EP claimed
WO-2003004493-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2003-01-16 — — WO claimed
US-12630487-B2 Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 — — US disclosed
US-4374990-A ANTIDEPRESSANTS HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075966-A1 Substituted Dihydroimidazoles and their Use in the Treatment of Tumors TP53, KRAS, NRAS SIGMAR1 4263/4885CXCR4 2169/4885MEN1 1376/4885
US-12630487-B2 Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine AZI2, ALKBH2, MGMT SIGMAR1 1641/4885CXCR4 2296/4885MEN1 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.